Investigational Drug Details
| Drug ID: | D149 |
| Drug Name: | Gemcabene |
| Synonyms: | Gemcabene |
| Type: | Chemical drug |
| DrugBank ID: | DB05123 |
| DrugBank Description: | Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C). |
| PubChem ID: | 157692 |
| CasNo: | 183293-82-5 |
| Repositioning for NAFLD: | No |
| SMILES: | CC(C(O)=O)(C)CCCCOCCCCC(C)(C)C(O)=O |
| Structure: |
|
| InChiKey: | SDMBRCRVFFHJKR-UHFFFAOYSA-N |
| Molecular Weight: | 302.411 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | Investigated for use/treatment in atherosclerosis, cardiovascular disorders, and hyperlipidemia. |
| Targets: | ACC inhibitor; apo C-III inhibitor; CRP inhibitor; CCR2 receptor antagonist; CCR5 receptor antagonist; lipoprotein A inhibitor; PPAR agonist; sulfatase inhibitor |
| Therapeutic Category: | Enhance lipid metabolism; Anti-fibrosis |
| Clinical Trial Progress: | Phase 2 terminated (NCT03436420: Terminated due to lack of efficacy and safety concerns.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0092 | NCT03436420 | Phase 2 | Terminated | Has Results | March 29, 2018 | December 31, 2020 | Details |
| L0360 | NCT03508687 | Phase 1/Phase 2 | Completed | Has Results | March 13, 2018 | August 17, 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T24 | C-C chemokine receptor type 2 | CCR2 | antagonist | GPCR | P41597 | CCR2_HUMAN | Details |
| T25 | C-C chemokine receptor type 5 | CCR5 | antagonist | GPCR | P51681 | CCR5_HUMAN | Details |
| T18 | Acetyl-CoA carboxylase 1 | ACACA | inhibitor | Enzyme | Q13085 | ACACA_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |